ATE509955T1 - Humanisierte kollagen-antikörper und damit verbundene verfahren - Google Patents

Humanisierte kollagen-antikörper und damit verbundene verfahren

Info

Publication number
ATE509955T1
ATE509955T1 AT02795695T AT02795695T ATE509955T1 AT E509955 T1 ATE509955 T1 AT E509955T1 AT 02795695 T AT02795695 T AT 02795695T AT 02795695 T AT02795695 T AT 02795695T AT E509955 T1 ATE509955 T1 AT E509955T1
Authority
AT
Austria
Prior art keywords
related methods
collagen antibodies
cdrs
specific binding
binding activity
Prior art date
Application number
AT02795695T
Other languages
English (en)
Inventor
Jeffry Watkins
William Huse
Ying Tang
Daniel Broek
Peter C Brooks
Original Assignee
Cell Matrix Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/995,529 external-priority patent/US7365167B2/en
Application filed by Cell Matrix Inc filed Critical Cell Matrix Inc
Application granted granted Critical
Publication of ATE509955T1 publication Critical patent/ATE509955T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6843—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT02795695T 2001-11-26 2002-11-26 Humanisierte kollagen-antikörper und damit verbundene verfahren ATE509955T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/995,529 US7365167B2 (en) 2001-11-26 2001-11-26 Humanized collagen antibodies and related methods
US10/011,250 US7390885B2 (en) 2001-11-26 2001-12-06 Humanized collagen antibodies and related methods
PCT/US2002/038147 WO2003046204A2 (en) 2001-11-26 2002-11-26 Humanized collagen antibodies and related methods

Publications (1)

Publication Number Publication Date
ATE509955T1 true ATE509955T1 (de) 2011-06-15

Family

ID=26682164

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02795695T ATE509955T1 (de) 2001-11-26 2002-11-26 Humanisierte kollagen-antikörper und damit verbundene verfahren

Country Status (12)

Country Link
US (4) US7390885B2 (de)
EP (1) EP1478764B1 (de)
JP (2) JP4519464B2 (de)
CN (1) CN1596313B (de)
AT (1) ATE509955T1 (de)
AU (1) AU2009200070A1 (de)
CA (1) CA2468016A1 (de)
HK (1) HK1076128A1 (de)
IL (1) IL162117A0 (de)
MX (1) MXPA04004857A (de)
NZ (1) NZ533408A (de)
WO (1) WO2003046204A2 (de)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7658924B2 (en) 2001-10-11 2010-02-09 Amgen Inc. Angiopoietin-2 specific binding agents
US7365167B2 (en) 2001-11-26 2008-04-29 Cell Matrix, Inc. Humanized collagen antibodies and related methods
US7541440B2 (en) * 2002-09-30 2009-06-02 Immunomedics, Inc. Chimeric, human and humanized anti-granulocyte antibodies and methods of use
EP2168986A3 (de) 2004-02-19 2010-07-28 Genentech, Inc. Antikörper mit korrigiertem CDR
US20070048325A1 (en) * 2005-08-24 2007-03-01 Dennis Van Epps Combination therapies for inhibiting integrin-extracellular matrix interactions
EP2054442A2 (de) * 2006-06-14 2009-05-06 Cell-Matrix, Inc. Denaturierte collagen-peptide und anwendungen davon
RU2499001C2 (ru) * 2006-06-30 2013-11-20 Ново Нордиск А/С Антитела к nkg2a и их применения
CN103408661B (zh) * 2007-01-05 2016-04-06 苏黎世大学 提供疾患特异性结合分子和靶的方法
US8048420B2 (en) 2007-06-12 2011-11-01 Ac Immune S.A. Monoclonal antibody
US8613923B2 (en) 2007-06-12 2013-12-24 Ac Immune S.A. Monoclonal antibody
EP2238166B1 (de) 2007-10-05 2013-11-27 Genentech, Inc. Verwendung eines anti-amyloid-beta-antikörpers bei augenkrankheiten
JO2913B1 (en) 2008-02-20 2015-09-15 امجين إنك, Antibodies directed towards angiopoietin-1 and angiopoietin-2 proteins and their uses
WO2010055950A1 (ja) * 2008-11-17 2010-05-20 財団法人ヒューマンサイエンス振興財団 癌間質の構成因子に対して特異的結合能を有する物質と抗腫瘍性化合物との複合体による新規の癌ターゲティング治療
WO2010115749A2 (en) * 2009-03-30 2010-10-14 Nordic Bioscience A/S Fibrosis biomarker assay
CA2773356A1 (en) * 2009-10-20 2011-04-28 Maine Medical Center Compositions and methods for treating inflammation and fibrosis
EP2544694B1 (de) * 2010-03-02 2018-10-31 Novelmed Therapeutics, Inc. Verfahren zur hemmung von durch alternative pfade vermittelten störungen mit antikörpern gegen properdin zur hemmung von c5-interaktionen mit properdin
SG187173A1 (en) 2010-07-30 2013-02-28 Ac Immune Sa Safe and functional humanized anti beta-amyloid antibody
CA2820590A1 (en) * 2010-11-10 2012-05-18 Nippon Kayaku Kabushiki Kaisha Anti single-strand type-iv collagen polypeptide antibody, and pharmaceutical, or agent for diagnosing, preventing or treating tumours, containing same
WO2013041844A2 (en) * 2011-09-19 2013-03-28 Kymab Limited Antibodies, variable domains & chains tailored for human use
WO2013158217A1 (en) 2012-04-20 2013-10-24 Thomas Jefferson University Engineered antibody for inhibition of fibrosis
CN104870474B (zh) 2012-10-04 2019-03-12 诺沃姆德治疗公司 用于治疗溶血性疾病的旁路途径特异性抗体
US9725520B2 (en) 2013-03-14 2017-08-08 The Board Of Regents Of The University Of Texas System HER3 specific monoclonal antibodies for diagnostic and therapeutic use
RU2759334C2 (ru) * 2016-09-21 2021-11-12 Нексткьюр, Инк. Антитела против siglec-15 и способы их применения
KR20210093251A (ko) * 2018-10-16 2021-07-27 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 암 및 다른 질환의 진단 및 치료를 위한 병원성 세포외 매트릭스의 동정 및 표적화
JP2022513053A (ja) * 2018-11-16 2022-02-07 アルバート アインシュタイン カレッジ オブ メディスン Ｂ７－Ｈ３のＩｇＶドメインに対するモノクローナル抗体及びその使用
AU2020213565A1 (en) * 2019-01-28 2021-08-05 Tuojie Biotech (Shanghai) Co., Ltd. Anti-CD79B antibody, antigen-binding fragment thereof, and pharmaceutical use thereof
WO2021252974A2 (en) * 2020-06-11 2021-12-16 Proviva Therapeutics (Hong Kong) Limited Collagen-targeted fusion proteins and antibodies
WO2022147298A1 (en) * 2020-12-31 2022-07-07 Seattle Children's Hospital D/B/A Seattle Children's Research Institute Vascular-endothelial cadherin activating antibodies and uses thereof

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US91482A (en) * 1869-06-15 Improvement in harvesters
US4342566A (en) 1980-02-22 1982-08-03 Scripps Clinic & Research Foundation Solid phase anti-C3 assay for detection of immune complexes
JPS6019790A (ja) 1983-07-14 1985-01-31 Yakult Honsha Co Ltd 新規なカンプトテシン誘導体
DE3587500T2 (de) 1984-12-04 1993-12-16 Lilly Co Eli Tumorbehandlung bei Säugetieren.
US5092885A (en) 1987-02-12 1992-03-03 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Peptides with laminin activity
US5320970A (en) 1987-11-06 1994-06-14 Washington Research Foundation Detection of collagen degradation in vivo
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US6020145A (en) 1989-06-30 2000-02-01 Bristol-Myers Squibb Company Methods for determining the presence of carcinoma using the antigen binding region of monoclonal antibody BR96
US5112946A (en) 1989-07-06 1992-05-12 Repligen Corporation Modified pf4 compositions and methods of use
US5192744A (en) 1990-01-12 1993-03-09 Northwestern University Method of inhibiting angiogenesis of tumors
EP0470569B1 (de) 1990-08-08 1995-11-22 Takeda Chemical Industries, Ltd. Intravaskulär embolisierendes Mittel mit Gehalt an einem die Angiogenesis hemmenden Stoff
US5264563A (en) 1990-08-24 1993-11-23 Ixsys Inc. Process for synthesizing oligonucleotides with random codons
US5871974A (en) 1990-09-28 1999-02-16 Ixsys Inc. Surface expression libraries of heteromeric receptors
JP3105629B2 (ja) 1991-04-23 2000-11-06 サングスタット メディカル コーポレイション 特異的結合ペアのメンバーの細胞活性調節接合体
ES2145004T3 (es) 1991-08-21 2000-07-01 Novartis Ag Derivados de anticuerpos.
DE4127790A1 (de) 1991-08-22 1993-02-25 Wank Anna Verwendung von oligopeptiden mit 2 bis 5 peptidbindungen fuer kosmetische zwecke und einige neue oligopeptid-metallkomplexe
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
JPH0675216A (ja) 1992-08-27 1994-03-18 Hitachi Ltd 液晶表示装置
US6132976A (en) 1992-12-04 2000-10-17 Shriners Hospitals For Children Immunoassays for the measurement of collagen denaturation and cleavage in cartilage
AU5558394A (en) 1992-12-04 1994-07-04 Shriners Hospitals For Crippled Children Immunoassay for the measurement of collagen cleavage in cartilage
US5541295A (en) 1993-02-12 1996-07-30 The Board Of Governors For Higher Education State Of Rhode Island And Providence Plantations Detection of type II collagen and its peptides
ES2122231T3 (es) 1993-07-28 1998-12-16 Boehringer Mannheim Gmbh Inmunoanalisis para la deteccion de colageno tipo i o fragmentos de colageno correspondientes.
US5510391A (en) 1993-10-22 1996-04-23 Mayapple Holdings, Llc Method of treating blood vessel disorders of the skin using vitamin K
US5465826A (en) 1994-02-24 1995-11-14 Valiant Machine & Tool, Inc. Conveyor system
US5560910A (en) 1994-08-26 1996-10-01 Crandall; Wilson T. Topical anti-inflammatory composition and method
US5763272A (en) 1994-12-23 1998-06-09 Boehringer Mannheim Gmbh Hybridoma for producing antibody for collagen I
US5783184A (en) 1994-12-23 1998-07-21 Smithkline Beecham Corporation Method for treatment and diagnosis of IL-5 mediated disorders
US5756775A (en) 1995-12-13 1998-05-26 Eli Lilly And Company Process to make α,α-difluoro-β-hydroxyl thiol esters
US6001994A (en) 1995-12-13 1999-12-14 Eli Lilly And Company Process for making gemcitabine hydrochloride
WO1997039746A1 (en) 1996-04-22 1997-10-30 Advanced Polymer Systems, Inc. Method of and composition for treating disorders of the skin using vitamin k
AU3304597A (en) 1996-05-23 1997-12-09 Shriners Hospital For Children Cartilage type ii collagen as an angiogenic factor
US6492508B1 (en) 1996-06-03 2002-12-10 United States Surgical Corp. A Division Of Tyco Healthcare Group Nucleic acids encoding extracellular matrix proteins
US6590079B2 (en) * 1997-01-30 2003-07-08 Ixsys, Incorporated Anti-αvβ3 recombinant human antibodies, nucleic acids encoding same
GB9702252D0 (en) 1997-02-06 1997-03-26 Univ Sheffield Medical The Sch Collagen assay
US5817699A (en) 1997-05-30 1998-10-06 Flores; John A. Process for the preparation of ketamine ointment
JP2001512143A (ja) 1997-07-31 2001-08-21 メトラ バイオシステムズ， インコーポレイテッド コラーゲン−ペプチドアッセイ法
WO1999006834A2 (en) 1997-08-04 1999-02-11 Ixsys, Incorporated Methods for identifying ligand specific binding molecules
AU5155198A (en) 1997-08-28 1999-03-22 Robert Murdock Method and composition for transdermal administration of pharmacologic agent
US6030792A (en) 1997-11-13 2000-02-29 Pfizer Inc Assays for measurement of protein fragments in biological media
ES2246093T3 (es) 1998-10-16 2006-02-01 Fraunhofer-Gesellschaft Zur Forderung Der Angewandten Forschung E.V. Patogenicida molecular que induce una resistencia a la enfermedad en las plantas.
US6833373B1 (en) 1998-12-23 2004-12-21 G.D. Searle & Co. Method of using an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
PT1149111E (pt) 1999-01-06 2009-11-19 Univ Southern California Processo e composição para a inibição da angiogénese
US6521593B1 (en) 1999-02-01 2003-02-18 Childrens Hospital Los Angeles Methods for inhibiting brain tumor growth
US6531580B1 (en) 1999-06-24 2003-03-11 Ixsys, Inc. Anti-αvβ3 recombinant human antibodies and nucleic acids encoding same
AU783019B2 (en) 1999-07-13 2005-09-15 University Of Southern California Novel method and composition for inhibition of angiogenesis using antagonists based on MMP-9 and beta1 integrins
AU760486B2 (en) 1999-10-13 2003-05-15 Incyte Genomics, Inc. Multiplex cytokine analysis
US6849425B1 (en) 1999-10-14 2005-02-01 Ixsys, Inc. Methods of optimizing antibody variable region binding affinity
AU2001233277B2 (en) 2000-02-03 2004-06-03 Millennium Pharmaceuticals, Inc. Humanized anti-ccr2 antibodies and methods of use therefor
AU2001243515A1 (en) 2000-03-08 2001-09-17 Rhode Island Hospital, A Lifespan Partner Combination drug therapy
US6696254B2 (en) 2001-11-21 2004-02-24 Kimberly-Clark Worldwide, Inc. Detection and identification of enteric bacteria
US7365167B2 (en) 2001-11-26 2008-04-29 Cell Matrix, Inc. Humanized collagen antibodies and related methods
US20040241776A1 (en) 2003-05-22 2004-12-02 Agdia, Inc. Multiplex enzyme-linked immunosorbent assay for detecting multiple analytes
JP2005347062A (ja) 2004-06-02 2005-12-15 Hitachi Displays Ltd バックライト装置及び液晶表示装置
JP2006075216A (ja) 2004-09-07 2006-03-23 Toshiba Corp 医用画像処理システム、医用画像処理プログラムおよび医用画像処理方法
EP2054442A2 (de) 2006-06-14 2009-05-06 Cell-Matrix, Inc. Denaturierte collagen-peptide und anwendungen davon

Also Published As

Publication number Publication date
CA2468016A1 (en) 2003-06-05
US7390885B2 (en) 2008-06-24
AU2002360439A2 (en) 2003-06-10
JP4519464B2 (ja) 2010-08-04
EP1478764B1 (de) 2011-05-18
WO2003046204A8 (en) 2004-07-08
US20070077199A1 (en) 2007-04-05
WO2003046204A2 (en) 2003-06-05
WO2003046204A3 (en) 2004-09-23
JP2009240324A (ja) 2009-10-22
US20100303726A1 (en) 2010-12-02
IL162117A0 (en) 2005-11-20
HK1076128A1 (en) 2006-01-06
US20080260733A1 (en) 2008-10-23
AU2002360439A1 (en) 2003-06-10
AU2009200070A1 (en) 2009-02-05
US7763248B2 (en) 2010-07-27
US20080050388A1 (en) 2008-02-28
EP1478764A4 (de) 2007-05-23
MXPA04004857A (es) 2005-04-11
US7566770B2 (en) 2009-07-28
NZ533408A (en) 2006-06-30
CN1596313B (zh) 2010-05-26
EP1478764A2 (de) 2004-11-24
CN1596313A (zh) 2005-03-16
JP2005510246A (ja) 2005-04-21

Similar Documents

Publication Publication Date Title
ATE509955T1 (de) Humanisierte kollagen-antikörper und damit verbundene verfahren
IN2009KN02655A (de)
IL220128A0 (en) Method for the humanization of antibodies and humanized antibodies thereby obtained
ATE454903T1 (de) Gegen menschliches ovarialkarzinom und gegen cd3 gerichteter bispezifischer antikörper
WO2005069970A3 (en) Antibody specificity transfer using minimal essential binding determinants
WO2003100008A3 (en) Neutralizing human anti-igfr antibody
NZ594466A (en) Human monoclonal antibodies to protein tyrosine kinase 7 (PTK7) and methods for using anti-PTK7 antibodies
GEP20094829B (en) Fully human antibodies against human 4-1bb (cd137)
NO20054351L (no) Monoklonalt antistoff og hybridom som produserer dette
GEP20074222B (en) Antibodies to cd40
RS80704A (en) ANTI- av?6.ANTIBODIES
WO2006071441A3 (en) Antibodies directed to gpnmb and uses thereof
CR20130153A (es) PROTEÍNAS DE LA UNIÓN A IL-12/P40 (Divisional 9599)
WO2003060080A3 (en) Canine immunoglobulin variable domains, caninized antibodies, and methods for making and using them
MX2007000103A (es) Bibliotecas de anticuerpos universales.
DK1308507T3 (da) Monoklonalt antistof mod HCV-kerneantigen
DK0500659T3 (da) Monoklonale antistoffer.
WO2002074251A3 (en) Monoclonal antibody therapy for pancreas cancer

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties